ESMO Asia 2025 | The upcoming role of ADCs and immunotherapy in bladder cancer in 2026
Christof Vulsteke, MD, PhD, AZ Maria Middelares, Ghent, Belgium, describes the significance of combining immunotherapy (IO) with antibody-drug conjugates (ADCs) in the treatment of bladder cancer, highlighting that this approach has been a major development in the field in recent years. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think it’s the first one that has it read out in the perioperative space of ADC plus IO as a phase three trial. So I think EVP is a first and other smaller phase two also looking at combining IO with antibody drug conjugate with another payload, another target like TROP2, payload like TOP1. But I think this is the first that has this robust data as a phase three trial...
I think it’s the first one that has it read out in the perioperative space of ADC plus IO as a phase three trial. So I think EVP is a first and other smaller phase two also looking at combining IO with antibody drug conjugate with another payload, another target like TROP2, payload like TOP1. But I think this is the first that has this robust data as a phase three trial. So the antinectin IV MMAE payload together with checkpoint inhibition, I think is the first that has this big phase three data. So the others still have to come, but I think the combination of IO and ADC is the most prominent thing that has happened over the recent years of bladder cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
